Global Size of Biologics Contract Development Market Expected to Surpass USD 13.22 Billion by 2030, at 10.4% CAGR: Polaris Market Research

[115+ Pages Research Study] According to Polaris Market Research report, the global biologics contract development market size & share expected to generate revenue of USD 13.22 Billion by 2030 and estimated to be valued at USD 5.48 billion in 2021, at a compound annual growth rate (CAGR) of 10.4% from 2022 to 2030. The top market company profiles included in report with their sales, revenues and strategies are Abzena Ltd, AGC Biologics, Ajinomoto Bio-Pharma, Almac, Avid Bioservices, Inc; Bionova Scientific Inc, BioXcellence (Boehringer Ingelheim Biopharmaceuticals GmbH) and Others.

New York, NY, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Polaris Market Research has published a new research report titled “Biologics Contract Development Market Share, Size, Trends, Industry Analysis Report, By Source (Mammalian, Microbial, Others); By Indication; By Product Service; By Region; Segment Forecast, 2022 - 2030” in its research database.

“According to the latest research study, the global biologics contract development market size & share are expected to generate revenue of USD 13.22 Billion by 2030 and are estimated to be valued at USD 5.48 Billion in 2021, at a compound annual growth rate (CAGR) of 10.4% from 2022 to 2030”.

What is Biologics Contract Development? What is Expected Size & Share of Biologics Contract Development Market?

  • Overview

Biologics contract development and manufacturing organization (CDMO) provides a full range of services from drug development to drug manufacturing to pharmaceutical and biotech companies. This type of contract development may focus on the development and manufacturing of biologics alone, or they may offer the same services for both biologics and small-molecule drugs. When a pharmaceutical company plans to launch a new drug product in the marketplace, it may choose to partner with a biologics CDMO for the clinical development and manufacturing part of the process.

CDMOs provide various services such as clinical research and development, a smooth manufacturing process, efficient packaging services, formulation guidance, and analytical and regulatory support, among others. The biologics contract development market size is experiencing immense growth due to the increasing outsourcing of R&D by pharma and biopharma businesses and the growing adoption of novel technologies for biological manufacturing.

Request Sample Copy of Biologics Contract Development Market Research Report @

(The sample of this report is readily available on request. The report sample contains a brief introduction to the research report, a Table of Contents, a Graphical introduction of regional analysis, Top players in the market with their revenue analysis, and our research methodology.)

Our Sample Report May Includes:

  • 2030 Updated Report Introduction, Overview, and In-depth industry analysis.
  • 115+ Pages Research Report (Inclusion of Updated Research).
  • Provide Chapter-wise guidance on Requests.
  • 2022 Updated Regional Analysis with Graphical Representation of Size, Share & Trends
  • Includes Updated List of tables & figures.
  • Updated Report Includes Top Market Players with their Business Strategy, Sales Volume, and Revenue Analysis.

Highlights of The Report

  • All-inclusive information on the product portfolios of the top players in the market.
  • An in-depth assessment of the geographic and business segments of the market.
  • Market segmentation on the basis of the type of product, application, and region.
  • It offers a forward-looking perspective on the developing elements driving or controlling the business area’s development.
  • The recent research and development projects performed by each key player.
  • A thorough analysis of the market’s value chain and assess the effect of Porter’s five forces.

Some of the Top Market Players Are:

  • Abzena Ltd
  • AGC Biologics
  • Ajinomoto Bio-Pharma
  • Almac
  • Avid Bioservices Inc
  • Bionova Scientific Inc
  • BioXcellence (Boehringer Ingelheim Biopharmaceuticals GmbH)
  • Curia Global Inc.
  • Fujifilm Diosynth Biotechnologies
  • Genscript
  • KBI Biopharma
  • LakePharma
  • Lonza
  • STC Biologics
  • Samsung Biologics
  • Thermo Fisher Scientific Inc.
  • WuXi Biologics

For Additional Information on Key Players, Download a PDF Brochure:

Market Dynamics

Key Growth Driving Factors

  • A supportive regulatory environment for clinical trials is pushing the market growth

A favorable regulatory environment for clinical trials in developing countries is majorly propelling the biologics contract development market growth. Regulatory bodies in developing nations are synchronizing their policies with EMA and FDA standards in order to accelerate the approval process and create credibility. This is another factor boosting the biologics contract development industry expansion. Biologics contract research organizations aid businesses and institutions in completing the rising demand of the pharmaceutical and medical device industries with low R&D costs, which is expected to fuel the market growth during the forecast period.

Request for a Discount on this Report Before Purchase @

Recent Trending influencing the market

  • The rising prevalence of diseases fuels the market growth

Increased adoption of advanced technologies for biological development and a rising number of collaborations, mergers & acquisitions with local companies to develop biologic products are some of the key biologics contract development market trends positively influencing the market growth.

The growing prevalence of diseases, such as neurological disorders, gynecological disorders, cancer, ophthalmic disorders, and cardiovascular disorders, is further supporting the biologics contract development market sales. For instance, according to World Health Organization (WHO), cancer is one of the leading causes of death worldwide, accounting for nearly 10 million deaths in 2020.

Segmental Analysis

  • The mammalian source dominated the market

Based on the source, the mammalian source held the largest biologics contract development market share in 2021 because most research was carried out using mammalian cell lines. Also, the segment witnessed the share due to the key benefit of using mammalian cells for protein expression while creating mammalian proteins with suitable post-translational modifications that offer a native structure.  

The three most frequently used mammalian cell cultures to produce biopharmaceuticals are murine myeloma cells, baby hamster kidney (BHK21) cells, and Chinese hamster ovary (CHO) cells.

  • The process development services acquired the major market share

By product service, the process development services category dominated the market and is expected to maintain its dominance over the forecast period. Biologics process development can be characterized by two techniques, including upstream process development and downstream process development. The upstream process development is majorly utilized by the manufacturer to fulfill the client’s needs.

  • The oncology segment accounts for the highest revenue share

In terms of indication, the oncology category captured the greatest revenue share in the biologics contract development market. The key reason for the segment expansion is the increase in demand for therapy, as cancer can spread to any organ in the body. This is also leading to increased business investments in R&D and outsourcing.

Inquire more about this report before purchase @

(Inquire a report quote OR available discount offers to the sales team before purchase.)

Biologics Contract Development Market: Report Scope

Report Attribute Details
Revenue forecast in 2030 USD 13.22 Billion
Market size value in 2022 USD 5.97 Billion
Expected CAGR Growth 10.4% from 2022 - 2030
Base Year 2021
Forecast Year 2022 - 2030
Top Market Players Abzena Ltd, AGC Biologics, Ajinomoto Bio-Pharma, Avid Bioservices, Inc; Bionova Scientific Inc, BioXcellence (Boehringer Ingelheim Biopharmaceuticals GmbH), Curia Global, Inc., Fujifilm Diosynth Biotechnologies, Genscript, KBI Biopharma, LakePharma, Lonza, STC Biologics, Samsung Biologics, Thermo Fisher Scientific Inc., and WuXi Biologics.
Segments Covered By Source, By Product Service, By Indication, and By Region
Customization Options Customized purchase options are available to meet any research needs. Explore customized purchase options

Geographic Overview

  • North America is likely to register the fastest growth throughout the forecast period

By geography, the biologics contract development market in North America witnessed the highest market share owing to the increase in the number of strategic collaborations and acquisitions coupled with the growing demand for specialized testing services. Also, a surge in clinical trial activity and outsourcing activity is one of the key factors supporting the growth of contract development organizations (CDOs) in the region.

Moreover, the Asia Pacific region is anticipated to grow over the predicted period because biotechnology companies are increasingly investing in the Asia Pacific region owing to the changes made by various regulatory organizations to the clinical trial evaluation requirements to meet global needs.

Browse the Detail Report “Biologics Contract Development Market Share, Size, Trends, Industry Analysis Report, By Source (Mammalian, Microbial, Others); By Indication; By Product Service; By Region; Segment Forecast, 2022 - 2030” with in-depth TOC:    

For Additional Information OR Media Enquiry, Please Mail At:                                                                                                                

Recent Developments

  • In Jan 2022, Samsung Biologics acquired Biogen's 50% stake as a joint venture to strengthen biosimilar development capabilities and future performance in novel drug development.

Frequently Asked Questions

  • Who are the crucial companies operating the market?
  • What are the major industry norms influencing the development of the industry?
  • Which is the most propelling country in the industry?
  • Which application or product type will obtain progressive development possibilities during the forecast period?
  • What is the expected growth rate of the market during the foreseen period?

Polaris Market Research has segmented the biologics contract development market report based on source, product service, indication, and region:

By Source Outlook

  • Microbial
  • Mammalian
  • Others

By Product Service Outlook

  • Cell Line Development
  • Microbial
  • Mammalian
  • Others
  • Process Development
  • Upstream
  • Microbial
  • Mammalian
  • Others
  • Downstream
  • Impurity, isolation & identification
  • Physicochemical Characterization
  • Pharmaceutical Analysis
  • Others
  • By Product
  • MABs
  • Recombinant Proteins
  • Others
  • Others

By Indication Outlook

  • Oncology
  • Immunological Disorders
  • Cardiovascular Disorders
  • Hematological Disorders
  • Others

By Region Outlook

  • North America (U.S., Canada)
  • Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia)
  • Asia Pacific (Japan, China, India, Malaysia, Indonesia, South Korea)
  • Latin America (Brazil, Mexico, Argentina)
  • Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa)

Browse More Related Reports:

About Polaris Market Research

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR’s clientele spread across different enterprises. We at Polaris are obliged to serve PMR’s diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR’s customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR’s customers.


Likhil G
30 Wall Street
8th Floor,
New York City, NY 10005,
United States
Phone: +1-929 297-9727

Follow Us LinkedIn twitter